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Association Between Idiopathic Intracranial Hypertension
and Risk of Cardiovascular Diseases inWomen
in the United Kingdom
Nicola J. Adderley, PhD; Anuradhaa Subramanian, MSc; Krishnarajah Nirantharakumar, MD;
Andreas Yiangou, MBBS; KrishnaM. Gokhale, MSc; Susan P. Mollan, FRCOphth; Alexandra J. Sinclair, PhD
IMPORTANCE Cardiovascular disease (CVD) risk has not been previously evaluated in a large
matched cohort study in idiopathic intracranial hypertension (IIH).
OBJECTIVES To estimate the risk of composite cardiovascular events, heart failure, ischemic
heart disease, stroke/transient ischemic attack (TIA), type 2 diabetes, and hypertension in
womenwith idiopathic intracranial hypertension and compare it with the risk in women,
matched on bodymass index (BMI) and age, without the condition; and to evaluate the
prevalence and incidence of IIH.
DESIGN, SETTING, AND PARTICIPANTS This population-basedmatched controlled cohort study
used 28 years of data, from January 1, 1990, to January 17, 2018, from The Health
Improvement Network (THIN), an anonymized, nationally representative electronic medical
records database in the United Kingdom. All female patients aged 16 years or older were
eligible for inclusion. Female patients with IIH (n = 2760) were included and randomly
matched with up to 10 control patients (n = 27 125) by BMI and age.
MAIN OUTCOMES ANDMEASURES Adjusted hazard ratios (aHRs) of cardiovascular outcomes
were calculated using Cox regressionmodels. The primary outcomewas a composite of any
CVD (heart failure, ischemic heart disease, and stroke/TIA), and the secondary outcomes
were each CVD outcome, type 2 diabetes, and hypertension.
RESULTS In total, 2760womenwith IIH and 27 125 womenwithout IIH were included. Age
and BMI were similar between the 2 groups, with a median (interquartile range) age of 32.1
(25.6-42.0) years in the exposed group and 32.1 (25.7-42.1) years in the control group; in the
exposed group 1728 women (62.6%) were obese, and in the control group 16514 women
(60.9%) were obese. Higher absolute risks for all cardiovascular outcomes were observed in
womenwith IIH compared with control patients. The aHRs were as follows: composite
cardiovascular events, 2.10 (95% CI, 1.61-2.74; P < .001); heart failure, 1.97 (95% CI, 1.16-3.37;
P = .01); ischemic heart disease, 1.94 (95% CI, 1.27-2.94; P = .002); stroke/TIA, 2.27 (95% CI,
1.61-3.21; P < .001); type 2 diabetes, 1.30 (95% CI, 1.07-1.57; P = .009); and hypertension, 1.55
(95% CI, 1.30-1.84; P < .001). The incidence of IIH in female patients more than tripled
between 2005 and 2017, from 2.5 to 9.3 per 100000 person-years. Similarly, IIH prevalence
increased in the same period, from 26 to 79 per 100000women. Incidence increased
markedly with BMI higher than 30.
CONCLUSIONS AND RELEVANCE Idiopathic intracranial hypertension in women appeared to be
associated with a 2-fold increase in CVD risk; change in patient care to modify risk factors for
CVDmay reduce long-termmorbidity for womenwith IIH and warrants further evaluation.
JAMA Neurol. doi:10.1001/jamaneurol.2019.1812
Published online July 8, 2019.
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I diopathic intracranial hypertension (IIH) is a condition ofunknownorigincharacterizedbyelevated intracranialpres-sure typically manifesting as papilledema, with a conse-
quent risk of visual loss and chronic disablingheadache.1,2 In-
cidence and economic burden of IIH are rising in line with
globalobesity figures.3Diagnosticcriteria includebrain imaging
to excludemass lesion, hydrocephalus, andvenous thrombo-
sis aswell as the presence of papilledema and a lumbar punc-
ture pressure greater than25 cmcerebrospinal fluidwithnor-
mal constituents.4 Currently, management focuses on
preserving vision and reducing headache morbidity.5
Patientswith IIHare typically female, andmore than90%
of themareobese.6Bodymass index (BMI; calculatedasweight
in kilograms divided by height in meters squared) is associ-
atedwith the risk of IIH.7 Obesity is an established risk factor
for cardiovasculardisease (CVD)8 and type2diabetes.9,10Obe-
sity alone may confer a higher risk of CVD in IIH. Idiopathic
intracranial hypertension is characterized by a unique pro-
file of androgen excess affecting the cerebrospinal fluid
dynamics.11 Androgen excess is a key driver of increased
cardiovascular risk.12-17 We hypothesized that patients with
IIH may have an increased risk of cardiometabolic disease
compared with a cohort matched for obesity (BMI), age, and
sex. The aim of this study was to define cardiometabolic
risk in IIH, independent of BMI, and to identify trends in
prevalence and incidence.
Methods
Design and Data Source
Yearly prevalence was estimated by performing sequential
cross-sectional studies on January 1 each calendar year from
2005 to 2017. Annual IIH incidence rates for the same period
were identified by conducting a series of yearly cohort stud-
ies. Long-term cardiometabolic outcomes were assessed
through a retrospective population-based matched con-
trolled cohort study using data, dated January 1, 1990, to
January 17, 2018, from The Health Improvement Network
(THIN). The THIN data-collection scheme and research
using THIN data were approved by the NHS South-East Mul-
ticenter Research Ethics Committee in 2003. Under the
terms of this approval, studies must undergo independent
scientific review. Approval for the use of THIN data in this
present analysis was obtained from the Scientific Review
Committee in 2018. Because THIN data are anonymized,
individual patients are not required to give consent for the
use of their data.
The Health Improvement Network is a national database
ofelectronicprimarycarerecordsgeneralizable to theUKpopu-
lation. It contains coded information formore than 15million
patients from787primarycaregeneralpractices, includingpa-
tient demographics, symptoms, diagnoses, drug prescrip-
tions, consultations, and laboratory test results. Cardiovascu-
lar diseases, diabetes, and hypertension are included in the
Quality and Outcomes Framework, a scheme that incentiv-
izes appropriate identification and management of patients
with these diagnoses.18 Therefore, these conditions are well
coded inprimarycareandhavebeenextensively studied (eAp-
pendix 1 in the Supplement).19,20
Study Population
General practices were eligible for inclusion 1 year after re-
porting acceptablemortality rates (ameasure of data quality)
and 1 year after starting to use electronic medical records (to
ensure sufficient time for recording of comorbidities). For in-
cidence and prevalence, female patients of all ages who reg-
istered with an eligible general practice for 1 year ormore be-
fore cohort entry (to ensure documentation of all important
baseline covariates) were eligible for inclusion. In the cardio-
metabolicoutcomescohort,only femalesaged16yearsorolder
were included.
An IIH diagnosis was indicated by a record of a relevant
clinical (Read) code. In the United Kingdom, IIH is diagnosed
by hospital specialists according to diagnostic criteria4 and is
then communicated to general practices inwhich the clinical
code is entered into thepatient’s electronicmedical record.Pa-
tients with a clinical code for IIH and a simultaneous code for
hydrocephalus or cerebral venous thrombosis were excluded
to avoid the risk of miscoding.
In thecardiometabolicoutcomescohort study, for eachpa-
tient with IIH (exposed group), up to 10 controls were ran-
domly selected fromapool of age-, sex-, andBMI-matchedpa-
tients.Agewasmatched towithin 1year, andBMIwasmatched
towithin2kg/m2.Matchedcontrolpatientswere selectedwith
thismethod: Patientswith IIHwere identified, and their order
was shuffled by randomly permuting the patient list (follow-
ing theFisherYates algorithm)using a linear congruential gen-
erator as the source of randomness. Shuffling ensured that all
patients in the exposed group had an equal chance of being
matched to a control in instances inwhich a control individual
could potentially be matched with more than 1 exposed pa-
tient. When the required number (10) of possible control pa-
tientsforaparticularexposedpatientwasexceeded,a linearcon-
gruential generator provided a randomnumber between 1 and
thenumber of potential control patients. Thepotential control
at the position of this random number was selected. This pro-
cess was repeated for subsequent control patients.
Key Points
Question Is the risk of cardiovascular disease greater in women
with idiopathic intracranial hypertension than in women of the
same age and bodymass index but without idiopathic intracranial
hypertension?
Findings In this population-basedmatched controlled cohort
study of 2760 female patients with idiopathic intracranial
hypertension and 27 125 control patients, womenwith this
condition had twice the risk for cardiovascular disease compared
with their counterparts with similar bodymass index and age.
Between 2005 and 2017, the incidence and prevalence of
idiopathic intracranial hypertension have tripled.
Meaning Idiopathic intracranial hypertension appeared to be a
risk factor for cardiovascular disease in women; changing patient
management to address the risk factors for cardiovascular disease
may reduce long-termmorbidity.
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For patients with a new IIH diagnosis, the index date was
the date of diagnosis. For patients with a preexisting diagno-
sis, the index date was 1 year after the registration date. Con-
trol patients were assigned the same index date as their cor-
responding exposed patient to avoid immortal time bias.21
Patients with IIH and control patients were followed up from
the indexdateuntil the earliest of thesedates: outcomeevent,
death,patient left thegeneral practice, general practice ceased
contributing to the database, or study end.
The primary outcome was a composite of any CVD: heart
failure, ischemicheartdisease (IHD), andstrokeor transient is-
chemic attack (TIA). Secondary outcomeswere the cardiovas-
cular outcomes separately, type 2 diabetes, and hypertension.
Patientswitharecordof theoutcomeof interestatbaselinewere
excluded from the corresponding analysis; for CVD, patients
with a record of any CVD at baseline were excluded; for type 2
diabetes, patients with a record of type 1 or type 2 diabetes at
baseline were excluded.
Outcomes were defined by clinical codes. Ischemic heart
disease was defined in accordance with the Quality and Out-
comesFramework22definitionofcoronaryheartdisease,which
includedmyocardial infarction, angina, coronary atheroscle-
rosis, ischemic cardiomyopathy, and coronarymicrovascular
disease.
Covariates that might be associated with outcomes were
selected on the basis of biological plausibility and use in pre-
vious research. Covariates considered for all outcomes in-
cluded age, BMI, social deprivation, smoking status, current
lipid-loweringmedicationprescription, baseline recordofmi-
graine, andbaselinecardiometabolic conditions (excluding the
outcome). In theeventBMIwasnotavailable atbaseline, aBMI
recorded up to 90 days after the index date was used. Body
mass index was categorized as lower than 25 (underweight
to healthy weight), 25-30 (overweight), and higher than
30 (obese). Social deprivation was recorded as Townsend
deprivation quintile (scale: 1-5, with 1 indicating least
deprived).23 Smoking status was categorized as nonsmoker,
smoker, andex-smoker. Comorbiditiesweredefinedusing rel-
evant clinical codes.
Statistical Analysis
For point prevalence, the proportion of eligible female pa-
tients with any record ever of IIHwas calculated on January 1
each year from 2005 to 2017. Crude incidence rates of IIH for
every year from 2005 to 2017were calculated by dividing the
number of female patients with new IIH diagnosis (numera-
tor) by the total number of person-years at risk (denomina-
tor) for the given year. To describe incidence rates stratified
by age at diagnosis, baseline BMI, and Townsend deprivation
quintile, we used data for the whole period (2005-2017). To
estimate the independent associationof ageatdiagnosis, BMI,
andTownsenddeprivationquintilewith IIH incidence,wecal-
culated adjusted incidence rate ratios using Poisson regres-
sion, offsetting for person-years of follow-up. For themissing
data for BMI and Townsend deprivation quintile, a separate
missing category was created, which was included in the re-
gression analysis; BMI value was categorized asmissing if no
BMI was recorded at baseline or within 90 days of the index
date, or if the recorded value was outside the plausible range
(14-75).
In the cardiometabolic outcomes cohort study, crude haz-
ard ratios (HRs) and adjustedHRs (aHR) and their correspond-
ing95%CIswere calculatedusingCoxproportionalhazards re-
gression models. The proportional hazards assumption was
checked using log-log plots and the Schoenfeld residuals test.
For theprimaryoutcome (compositeCVD) andeachof the sec-
ondaryoutcomes (heart failure, IHD, stroke/TIA,diabetes, and
hypertension), 3 nested adjusted Cox models were assessed.
Model 1 was adjusted for the baseline patient demographic
variables: age, BMI (continuous), Townsenddeprivation quin-
tile, and smoking status. Model 2 was adjusted for baseline
demographic variables, current (up to 65 days before the
index date) lipid-lowering drug prescription, and baseline
cardiometaboliccomorbidities(forcardiovascularoutcomes:hy-
pertension and diabetes; for diabetes outcome: heart failure,
IHD, stroke/TIA, and hypertension; and for hypertension
outcome: heart failure, IHD, stroke/TIA, and diabetes). Model
3 included all model 2 covariates plus migraine. The Nelson-
Aalen cumulative hazard function was used to plot cumula-
tive hazard of primary and secondary outcomes.
In primary analysis, all prevalent and incident IIH diag-
noses were included. Because IIH is a rare disease, all female
patientswith adiagnosis of IIHwere included tomaximize the
sample size. However, a sensitivity analysis limited to pa-
tientswith incident IIH(newlydiagnosedafter registrationwith
the general practice) and the corresponding control patients
was performed to explore any association with survival bias.
Another sensitivity analysis limited towomendiagnosedwith
IIH at age 60 years or younger was carried out, because IIH is
rareamongolderadultsandmisclassificationerrormaybepres-
ent in those diagnosed older than age 60 years. Sensitivity
analyses were adjusted for covariates in model 2.
Body mass index was treated as a continuous variable.
Missing BMI data were replaced using multiple imputation.
Multiple imputationwas performed using chained equations
andpredictivemeanmatching.Valueswere imputedusing the
following covariates: age; Townsend deprivation quintile;
smoking status; baseline diabetes, hypertension, heart fail-
ure, IHD, and stroke/TIA; and current lipid-lowering drug
prescription.
Baselinecovariatesweresummarizedforbothexposedand
control groups using appropriate descriptive statistics: mean
(SD)andmedian (interquartile range [IQR]) for continuousvari-
ables, and number (%) for categorical variables. All analyses
wereperformedwithStata IC,version14 (StataCorpLLC).Two-
sided, unpaired P valueswere calculated using the t test. Sta-
tistical significance was set at P < .05.
Results
Prevalence of IIH in female patients increased from 26 per
100000 in2005 to 79per 100000 in2017 (Figure 1A, eTable 1
in the Supplement). Annual incidence of IIH in female pa-
tients increased from2.5per 100000person-years in 2005 to
9.3per 100000person-years in2017 (Figure1A). Incidencewas
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highest in the 20- to 29-year age group (16.5 per 100000 per-
son-years) followed by the 13- to 19-year age group (8.7 per
100000 person-years) and the 30- to 39-year age group (8.4
per 100000 person-years) (Figure 1B). Incidence of IIH in-
creasedwith increasingBMI (Figure 1C).After adjustments for
age at diagnosis and Townsend deprivation quintile, the inci-
dence rate ratio for IIH among patients with BMI of 25 to 30
was3.76 (95%CI,2.98-4.74;P < .001)andwithBMIhigher than
30 was 17.55 (95% CI, 14.41-21.36; P < .001), compared with
patients with BMI lower than 25 (eTable 2 in the Supple-
ment). Incidence of IIH also appeared to be higher among fe-
male patients who were in lower socioeconomic quintiles
(Figure 1D). However, after adjustments for age and BMI, the
trend was lost. The most-deprived Townsend quintile re-
mained statistically significantly associated with the
increased risk of IIH among female patients (incidence rate
ratio, 1.46; 95% CI, 1.22-1.77; P < .001).
In total, 2760 women with IIH (9.2%) and 27 125 women
without IIH (90.8%), matched for age and BMI, were
included in the analyses investigating cardiometabolic out-
comes. The median (IQR) follow-up time was 3.5 (1.3-7.5)
years. Baseline characteristics of female patients with IIH
(exposed group) and without IIH (control group) are pre-
sented in Table 1. At cohort entry, age and BMI were similar
between the 2 groups, with a median (IQR) age of 32.1 (25.6-
42.0) years in the exposed group and 32.1 (25.7-42.1) years
in the control group; in the exposed group 1728 women
(62.6%) were obese, and in the control group 16 514 women
(60.9%) were obese. Women with IIH, compared with those
without, were slightly more likely to be smokers (849
[30.8%] vs 6134 [22.6%]) or ex-smokers (502 [18.2%] vs
4573 [16.9%]). Women with IIH had substantially higher
migraine, CVD, and hypertension at baseline compared with
female patients without IIH.
Crude incidence rate of composite cardiovascular events
was 5.31 per 1000 person-years among women in the ex-
posed group, with a crude HR of 2.15 (95% CI, 1.66-2.79;
P < .001), andwas 2.47 per 1000person-years amongwomen
in the control group.Adjusting for baselinedemographic vari-
ables and cardiovascular risk factors (model 2)marginally re-
ducedtheeffectestimate (aHR,2.10;95%CI, 1.61-2.74;P < .001)
(Table 2; Figure 2 and Figure 3). Further adjusting for base-
line diagnosis of migraine (model 3) was not associated with
any changes in the results.
Figure 1. Prevalence and Incidence of Idiopathic Intracranial Hypertension in Female Patients, 2005-2017
90
80
70
60
10
20
30
40
50
0
An
nu
al
 P
re
va
le
nc
e 
pe
r 1
00
 0
00
 P
op
ul
at
io
n
14
12
10
8
2
4
6
0
Annual Incidence per 100 000 Person-Years
Annual incidence
Year
Trends in femalesA
18
16
14
12
2
4
6
8
10
0
In
ci
de
nc
e 
pe
r 1
00
 0
00
 P
er
so
n-
Ye
ar
s
Age Group, y
By ageB
35
30
25
20
5
10
15
In
ci
de
nc
e 
pe
r 1
00
 0
00
 P
er
so
n-
Ye
ar
s
BMI Category
By body mass indexC
9
8
7
6
1
2
3
4
5
0
In
ci
de
nc
e 
pe
r 1
00
 0
00
 P
er
so
n-
Ye
ar
s
Townsend Deprivation Quintile
By Townsend deprivation quintileD
2006 2007 2008 2009 2010 2011 20132012 2014 2015 2016 2017 0-12 13-19 20-29 30-39 40-49 50-59 60-69 ≥70
1 2 3 4 5
2005
0
<18.5 18.5-20 20-22 22-24 24-26 26-28 28-30 32-3430-32 34-36 36-38 38-40 >40
Annual prevalence
Bodymass index is calculated as weight in kilograms divided by height in meters squared. Townsend deprivation quintile scale: 1-5, with 1 being least deprived and 5
most deprived.
Research Original Investigation Association Between Idiopathic Intracranial Hypertension and Cardiovascular Risk inWomen
E4 JAMANeurology Published online July 8, 2019 (Reprinted) jamaneurology.com
Downloaded From: https://jamanetwork.com/ by a University of Birmingham User  on 07/10/2019
All adjusted HRs (model 2) for individual CVD outcomes
showedastatisticallysignificant increase inrisk inpatientswith
IIH:heart failure, 1.97 (95%CI, 1.16-3.37;P = .01); IHD, 1.94 (95%
CI, 1.27-2.94; P = .002); and stroke/TIA, 2.27 (95% CI, 1.61-
3.21; P < .001).
The association between IIH and composite cardiovas-
cular events remained statistically significant, with a similar
effect size, in the 2 sensitivity analyses performed (adjusted
for covariates inmodel 2). The HR from the sensitivity analy-
sis restricted topatientswith incident (newdiagnosis) IIHand
the corresponding control female patients was 3.14 (95% CI,
2.07-4.78; P < .001). The HR from the analysis restricted to
women who received a diagnosis before 60 years of age was
2.09 (95% CI, 1.58-2.75; P < .001).
For type 2 diabetes, the crude incidence rate was 9.8 per
1000person-years inwomenwith IIHand6.3per 1000person-
years in thosewithout IIH.ThecrudeHRwas1.55 (95%CI, 1.28-
1.87; P < .001). Adjusting for baseline demographic variables
andcomorbiditieswasassociatedwitha slight reduction in the
effect estimate (aHR, 1.30;95%CI, 1.07-1.57;P = .009) (Table2;
Figures 2 and 3).
Forhypertension, thecrudeincidenceratewas14.1per1000
person-years inwomenwith IIHand9.2per 1000person-years
in thosewithout IIH.ThecrudeHRwas 1.55 (95%CI, 1.30-1.84;
P < .001), andadjusting forbaselinedemographicvariablesand
comorbiditieswas not associatedwith any changes.
Sensitivity Analyses
In sensitivity analyses restricted to patients with incident
(newly diagnosed) IIH and their corresponding controls, the
median (IQR) age was 29.6 (24.2-38.2) years, and themedian
(IQR) follow-up was 3.1 (1.3-6.1) years. The association be-
tween IIHandcomposite cardiovascular events remained sta-
tistically significant,with a similar effect size (aHR, 3.14; 95%
CI, 2.07-4.78; P < .001). The association with type 2 diabetes
was lost (aHR, 0.82; 95% CI, 0.57-1.18; P = .28), and the asso-
ciation with hypertension remained statistically significant
withaslight increase ineffectestimate (aHR, 1.95;95%CI, 1.49-
2.56; P < .001) (eTable 3 in the Supplement).
In sensitivity analyses restricted to womenwho received
an IIH diagnosis before 60 years of age, the aHRs remained
similar to those in theprimary analyses: composite CVD, 2.09
(95%CI, 1.58-2.75;P < .001); diabetes, 1.35 (95%CI, 1.10-1.64;
P = .003); andhypertension, 1.60 (95%CI, 1.34-1.92;P < .001)
(eTable 3 in the Supplement).
Discussion
In this population-based matched controlled cohort study,
womenwith IIH hadmore than twice the risk of cardiovascu-
lareventscomparedwithcontrolpatientswithout IIHmatched
for BMI and age. Absolute risk for this young population was
low but noteworthy, considering the young age of the sample
and the relatively shortmedian follow-up (approximately 3½
years). The disease burden of IIH is growing, and its preva-
lenceand incidenceare risingannuallyandheightened in those
with obesity.
To our knowledge, no previous cohort study has evalu-
ated cardiovascular risk in IIH.24 This current study has
identified that an IIH diagnosis is statistically significantly
associated with increased risk of composite cardiovascular
events,heart failure, IHD,andstroke/TIA, independentofBMI.
This finding is the first indication that morbidity in IIH may
extendbeyond the typically consideredareasofvisual loss and
chronicheadaches,1,2,6,25 Thepredominantoccurrenceofobe-
sity in IIHmaybe expected to increase the cardiovascular risk
in these patients; however, these findings are apparent de-
spitematching for BMI and age and controlling for important
covariates.
Previous evidence has suggested an association between
migraine and increased risk of CVD.26 Migraine is diagnosed
in approximately80%ofpatientswith IIH.27 Therefore,we in-
cluded migraine as a covariate in model 3 to assess whether
Table 1. Baseline Characteristics ofWomenWith orWithout Idiopathic
Intracranial Hypertension
Variable
No. (%)
Women With IIH
(Exposed Group)
Women Without IIH
(Control Group)
Population 2760 (9.2) 27 125 (90.8)
Incident cohort 1331 (48.2) 12 679 (46.7)
Population aged <60 y 2709 (98.1) 25 811 (95.2)
Age, median (IQR), y 32.1 (25.62-42.00) 32.1 (25.71-42.06)
Townsend deprivation
quintile
1 (Least deprived) 361 (13.1) 4268 (15.7)
2 381 (13.8) 4397 (16.2)
3 532 (19.3) 5174 (19.1)
4 538 (19.5) 5122 (18.9)
5 (Most deprived) 454 (16.5) 4134 (15.2)
Missing data 494 (17.9) 4030 (14.9)
Smoking status
Nonsmoker 1284 (46.5) 15 058 (55.5)
Ex-smoker 502 (18.2) 4573 (16.9)
Smoker 849 (30.8) 6134 (22.6)
Missing data 125 (4.5) 1360 (5.0)
BMI, median (IQR) 34.80 (29.30-40.30) 34.30 (29.00-39.70)
BMI
<25 246 (8.9) 2561 (9.4)
25-30 416 (15.1) 4203 (15.5)
>30 1728 (62.6) 16 514 (60.9)
Missing data 370 (13.4) 3847 (14.2)
Current lipid
prescription
180 (6.5) 1572 (5.8)
Migraine 580 (21.0) 3247 (11.9)
Outcomes at baseline
Heart failure 8 (0.3) 58 (0.2)
IHD 35 (1.3) 245 (0.9)
Stroke/TIA 46 (1.7) 189 (0.7)
Hypertension 380 (13.8) 2500 (9.2)
Type 2 diabetes 130 (4.7) 1425 (5.2)
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); IHD, ischemic heart disease; IIH, idiopathic
intracranial hypertension; IQR, interquartile range; TIA, transient ischemic
attack.
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Table 2. Incidence Rates and Hazard Ratios for Cardiometabolic Outcomes inWomenWith orWithout
Idiopathic Intracranial Hypertension
Outcome Women With IIH (Exposed Group) P Value
Women Without IIH
(Control Group)
Composite CVD
Population, No. 2613 NA 26 356
Outcome events, No. (%) 68 (2.5) NA 328 (1.2)
Person-years 12 809 NA 132 930
Crude incidence rate per 1000
person-years
5.31 NA 2.47
Follow-up, median (IQR), y 3.50 (1.34-7.11) NA 3.72 (1.51-7.39)
Crude HR (95% CI) 2.15 (1.66-2.79) <.001 NA
Adjusted HR (95% CI)
Model 1a 2.10 (1.61-2.73) <.001 NA
Model 2b 2.10 (1.61-2.74) <.001 NA
Model 3c 2.08 (1.59-2.71) <.001 NA
Heart Failure
Population, No. 2735 NA 26 989
Outcome events, No. (%) 17 (0.6) NA 78 (0.3)
Person-years 13 445 NA 136 357
Crude incidence rate per 1000
person-years
1.26 NA 0.57
Follow-up, median (IQR), y 3.58 (1.38-7.26) NA 3.77 (1.52-7.50)
Crude HR (95% CI) 2.19 (1.30-3.71) .003 NA
Adjusted HR (95% CI)
Model 1a 1.99 (1.17-3.37) .01 NA
Model 2b 1.97 (1.16-3.37) .01 NA
Model 3c 1.97 (1.15-3.36) .01 NA
Ischemic Heart Disease
Population, No. 2698 NA 26 749
Outcome events, No. (%) 27 (0.9) NA 131 (0.5)
Person-years 13 216 NA 134 521
Crude incidence rate per 1000
person-years
2.04 NA 0.97
Follow-up, median (IQR), y 3.56 (1.37-7.20) NA 3.73 (1.51-7.42)
Crude HR (95% CI) 2.10 (1.39-3.18) <.001 NA
Adjusted HR (95% CI)
Model 1a 1.92 (1.27-2.91) .002 NA
Model 2b 1.94 (1.27-2.94) .002 NA
Model 3c 1.89 (1.24-2.88) .003 NA
Stroke/TIA
Population, No. 2674 NA 26 755
Outcome events, No. (%) 40 (1.5) NA 181 (0.7)
Person-years 13 115 NA 135 271
Crude incidence rate per 1000
person-years
3.05 NA 1.34
Follow-up, median (IQR), y 3.51 (1.34-7.17) NA 3.76 (1.52-7.47)
Crude HR (95% CI) 2.27 (1.61-3.19) <.001 NA
Adjusted HR (95% CI)
Model 1a 2.27 (1.61-3.21) <.001 NA
Model 2b 2.27 (1.61-3.21) <.001 NA
Model 3c 2.24 (1.58-3.17) <.001 NA
Hypertension
Population, No. 2232 NA 23 566
Outcome events, No. (%) 148 (6.2) NA 1059 (4.3)
Person-years 10 505 NA 115 800
(continued)
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comorbidmigrainewasa factor in theobserved increase inCVD
risk; however, the results were unaffected, suggesting no as-
sociation.
Idiopathic intracranial hypertensionwas associatedwith
a 30% increase in risk of diabetes and a 55% increase in risk of
hypertension in women, independent of BMI and age and af-
ter accounting forpotential confounders. Ina sensitivityanaly-
sis limited to female patients with new IIH diagnosis, the as-
sociation with diabetes was lost. The reason for this lost
associationmay be the younger age of patients with incident
IIH (median age of 29 years) and the relatively short fol-
low-up (median length of 3 years), given that onset and diag-
nosis of type 2 diabetes typically occur at an older age (as
reflected in the cumulative hazard plot [Figure 3]).
The underlying mechanisms of the increased cardiovas-
cular risk in IIH are not established. Higher cardiovascular
riskwould be estimated in anobese population, but itwas ob-
served despitematching to an obese control population. This
finding adds support to the concept that cardiovascular risk
in IIH is not exclusively associated with obesity, and it points
to a more complex disease characterized by systemic meta-
bolic dysregulation. Centripetal fat accumulation is key inde-
termining the risk ofmetabolic syndrome and CVD.28-30 Cen-
tripetal fat predominance has been identified in IIH and
correlates with intracranial pressure.31 Whether obesity is
causal in IIH, or if it represents a comorbiditydrivenby theun-
derlyingmetabolic disease state, is unclear. However, weight
loss is associated with resolution of IIH.32 Evaluating the
Table 2. Incidence Rates and Hazard Ratios for Cardiometabolic Outcomes inWomenWith orWithout
Idiopathic Intracranial Hypertension (continued)
Outcome Women With IIH (Exposed Group) P Value
Women Without IIH
(Control Group)
Crude incidence rate per 1000
person-years
14.09 NA 9.15
Follow-up, median (IQR), y 3.20 (1.26-6.40) NA 3.48 (1.43-6.94)
Crude HR (95% CI) 1.55 (1.30-1.84) <.001 NA
Adjusted HR (95% CI)
Model 1a 1.53 (1.29-1.82) <.001 NA
Model 2d 1.55 (1.30-1.84) <.001 NA
Model 3c 1.55 (1.30-1.84) <.001 NA
Type 2 Diabetes
Population, No. 2510 NA 24 901
Outcome events, No. (%) 120 (4.6) NA 799 (3.1)
Person-years 12 300 NA 125 947
Crude incidence rate per 1000
person-years
9.76 NA 6.34
Follow-up, median (IQR), y 3.49 (1.34-6.94) NA 3.62 (1.47-7.27)
Crude HR (95% CI) 1.55 (1.28-1.87) <.001 NA
Adjusted HR (95% CI)
Model 1a 1.32 (1.09-1.61) .005 NA
Model 2e 1.30 (1.07-1.57) .009 NA
Model 3c 1.29 (1.06-1.57) .01 NA
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided by height in meters squared);
CVD, cardiovascular disease; HR, hazard ratio; IHD, ischemic heart disease; IIH, idiopathic intracranial hypertension;
IQR, interquartile range; NA, not applicable; TIA, transient ischemic attack.
a Model 1 adjusted for age, BMI (continuous), Townsend deprivation quintile (scale: 1-5, with 1 indicating least deprived),
and smoking status.
bModel 2 adjusted for all covariates in model 1 plus current (up to 65 days prior to index date) lipid-lowering drug
prescription and baseline hypertension and diabetes.
c Model 3 included all model 2 covariates plus migraine.
dModel 2 adjusted for all covariates in model 1 plus current (up to 65 days prior to index date) lipid-lowering drug
prescription and baseline IHD, heart failure, stroke/TIA, and hypertension.
e Model 2 adjusted for all covariates in model 1 plus current (up to 65 days prior to index date) lipid-lowering drug
prescription and baseline IHD, heart failure, stroke/TIA, and diabetes.
Figure 2. Composite Outcomes AmongWomenWith orWithout
Idiopathic Intracranial Hypertension
Decreased
Risk
Increased
Risk
1010.1
HR (95% CI)
Outcome
Adjusted HR
(95% CI)
Compound CVD 2.10 (1.61-2.74)
Heart failure 1.97 (1.16-3.37)
IHD 1.94 (1.27-2.94)
Stroke/TIA 2.27 (1.61-3.21)
Hypertension 1.55 (1.30-1.84)
Type 2 diabetes 1.30 (1.07-1.57)
CVD indicates cardiovascular disease; HR, hazard ratio; IHD, ischemic heart
disease; and TIA, transient ischemic attack.
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associationofweightmodificationwith cardiovascular risk in
IIH is of future interest.
To date, IIH has been considered a rare condition, with re-
ported incidence of 1 to 3 per 100000 in the general popula-
tion, but IIH incidence has been speculated to be rising, sec-
ondary to theobesityepidemic thathasbeenspreadingglobally
over the past 40 years.1,33 In this large cohort study, recorded
prevalenceand incidenceof IIHtripledbetween2005and2017,
mirroring other reports.3,34 Incidence is highest in female pa-
tientsaged20to29years,with fewpatientsolder than50years
receiving a diagnosis. The condition ismuchmore frequent in
those who are overweight and obese, and the adjusted inci-
dence increases18-fold inthosewithaBMIhigher than30,com-
paredwith thosewith a BMI in the healthyweight range. Inci-
dence rises dramatically with a BMI of 30 or higher. Although
the rising IIH incidence rates are in line with growing obesity
Figure 3. Cardiometabolic Outcomes inWomenWith (Exposed) orWithout (Control) Idiopathic Intracranial Hypertension
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rates, the numbers could also represent increased reporting of
this condition. However, cerebrospinal fluid shunt surgery for
IIH has also increased dramatically (320% increase in surgical
procedures between 1988 and 2002).35
Idiopathic intracranial hypertension occurrence in-
creased with higher Townsend deprivation levels. The asso-
ciationbetweensocialdeprivationandincreasedmorbidityand
mortality has been well established.36-40 The association be-
tween increased incidenceof IIHand themost-deprivedquin-
tile remained after adjustments for age and BMI, suggesting
that obesitymay not be the only factor in higher incidence in
the most deprived population.
Implications
This study has demonstrated increased cardiovascular risk in
patientswith IIH, despite their young age and independent of
BMI.These findingswould supportbroadening thecare forpa-
tients with IIH to include evaluating and modifying cardio-
vascular risk.
Patients with IIH are typically identified at a young age,
which could provide the opportunity for early assessment for
modifiable cardiovascular risk factors with subsequentman-
agement.Early intervention is likely to improve long-termcar-
diometabolic outcomesasnoted inotherdiseases.41,42Weight
loss can modify cardiometabolic disease risk, and it has also
been shown as a treatment for IIH.32 The role of bariatric sur-
gery tomodify IIH is being evaluated, but its associationwith
cardiometabolichealth in thecontextof IIH isalsoof interest.43
Future studies that comprehensively evaluate the clinical and
financial implicationsofmodifyingcardiometabolic risk for IIH
are important.
Strengths and Limitations
This studyhas several strengths, including its large sample size
used to evaluate a rare condition. In addition, the THIN pri-
mary care database is generalizable to the UK population and
has been found to be reliable.44,45 However, as with any rou-
tinely collected data, the use of this database presents poten-
tial biases, such as incorrect or inconsistent coding and in-
complete data. An IIH diagnosis necessitates a hospital
encounter for the diagnostic investigations,3 and the diagno-
sis is then reported to general practice or primary care physi-
cians; this process increases the likelihood that the diagnosis
in the primary care electronic record is correct, but accuracy
cannotbeguaranteed.Toensure that IIHmimicswerenotana-
lyzed,weexcludedpatientswithhydrocephalusor cerebralve-
nous sinus thrombosis and, ina sensitivity analysis, thosewho
received a diagnosis after 60 years of age. We used BMI at or
near the baseline date; however, weight may fluctuate over
time, and BMI at baseline may not be the same as that at the
time of IIH or outcome diagnosis for all patients. These re-
sults are limited by the relatively short median follow-up.
Headache painmay have reduced physical activity in the
exposed cohort. Physical activity was poorly recorded in pri-
mary care, and therefore adjusting for this potential con-
founder in the regressionmodels was not possible. However,
most of the women in the exposed and control cohorts were
obese; levels of physical activity are substantially lower in
people with obesity,46,47 and therefore any further reduction
inphysical activity in the IIHcohortwas likely tobe small. Fur-
thermore, we adjusted for other cardiometabolic risk factors,
such as hypertension, which are also associated with physi-
cal activity levels.48 In addition, recent researchhas shownno
difference in adipose tissue distribution31 or muscle mass, a
marker of physical activity,49-51 between individuals with IIH
andBMI-matched control patients (eAppendix 2 and the eFig-
ure in the Supplement). However, differences in physical ac-
tivity could have had an association with CVD outcomes.
These results may have been affected by surveillance bias
fromagreaternumberofcontactsbetweenpatientswithIIHand
healthcareprofessionals;however,becauseoftheserious,symp-
tomatic nature of the outcomes considered, this association is
likely tobesmall. IncreasedriskofCVDinpatientswith IIHmay
be partiallymediated by exposure to drugs, such as nonsteroi-
dalanti-inflammatorydrugs,duringthestudyperiod;wedidnot
account for thesemedications in the study design.
Conclusions
Womenwith IIH appeared tohave increased risk of CVDcom-
paredwithwomenwithout IIHwhowerematched forBMIand
age. The elevated risk of CVD is over and above that expected
from obesity alone, suggesting additional systemic meta-
bolic factors unique to IIH. Absolute risk in IIH remains low
but is important toknowgiven the rising incidenceof this con-
dition and the relatively young age of the patientswith IIHdi-
agnosis,whichprovidesanopportunity for intervention.Astep
change in clinical practice to include assessment andmanage-
ment of cardiovascular risk in IIH is likely to be advantageous
in efforts to improve long-term health outcomes for patients
and warrants further evaluation.
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